HOME >> BIOLOGY >> NEWS
Weizmann institute scientists solve the 3-D structure of the enzyme involved in Gaucher disease

Rehovot, Israel -- June 2, 2003 --An interdisciplinary team of Weizmann Institute scientists has solved the three-dimensional structure of an enzyme called glucocerebrosidase. Mutations occurring in this enzyme cause Gaucher disease, a genetic illness that mainly affects Ashkenazi Jews. The Institute study, published recently in EMBO Reports, may lead to the design of effective new therapies for treating the disease.

Gaucher disease was first described in 1882 by the French physician Philippe Gaucher. It is characterized by swelling and enlargement of the spleen and liver and disruption in the function of these organs, and in rare cases it also affects the brain. In the 1920s, the disease was found to be caused by the excessive accumulation of a fatty substance, or lipid, called glucosylceramide. In the 1960s, researchers discovered that the accumulation occurs due to a defect in the glucocerebrosidase enzyme, whose function is to break down this lipid and regulate its amount. In the 1980s, the gene responsible for manufacturing the enzyme was isolated; scientists found that mutations in this gene disrupt the function of the enzyme, leading to the development of Gaucher disease.

By the early 1990s, the U.S. company Genzyme started producing the enzyme first from placenta, then by genetic engineering. Today thousands of Gaucher patients are treated by injections of the enzyme, an approach called enzyme replacement therapy, or ERT. The annual cost of the therapy per patient is approximately $100,000 to $300,000. Obviously, more affordable alternatives, such as the ones that may emerge from the Weizmann Institute study, are urgently needed.

The Institute team included Prof. Tony Futerman of the Biological Chemistry Department, Prof. Joel Sussman of the Structural Biology Department and Prof. Israel Silman of the Neurobiology Department, as well as Dr. Michal Harel, Lilly Toker and graduate student Hay Dvir.

The first step in solving th
'"/>

Contact: Alex Smith
Alex_smith@margeotes.com
212-460-0563
American Committee for the Weizmann Institute of Science
1-Jun-2003


Page: 1 2

Related biology news :

1. Weizmann scientists invention moves forward: Cancer diagnosis technique gets FDA clearance
2. Psoriasis treatment based on Weizmann Institute Research passes phase II clinical trials
3. Weizmann Institute scientists report why taste and smell differ among individuals
4. Weizmann Institute scienists find that stem cells in the bone marrow become liver cells
5. Prize to Weizmann Institute professor for landmark work in stem cell transplantation
6. New witchweed-fighting method, presented by CIMMYT and Weizmann Institute scientist
7. Weizmann Institute scientists win global competition in predicting protein-protein interactions
8. Vaccination following spinal cord injury: Innovative Weizmann Institute approach limits paralysis
9. Weizmann Institute scientists block loss of eyesight in animals with a glaucoma-like disease
10. Weizmann Institute researcher named to Israel Academy Of Sciences And Humanities
11. Weizmann Institute scientists develop a novel system for analyzing genetic data that mimics the human capacity for unsupervised learning

Post Your Comments:
(Date:5/19/2015)... Research and Markets ( ... the  "Genetic Testing Market Outlook 2018"  report ... ,A recent report, Genetic Testing Market Outlook ... current and future genetic testing market. A ... principles and types are covered in this ...
(Date:5/14/2015)... 14, 2015  Verificient Technologies, Inc., a ... online remote proctoring, announced a new alliance ... and creator of the Canvas Learning Management ... companies will benefit from the seamless integration ... As a fully integrated multifactor biometrics behavioral ...
(Date:5/11/2015)... , May 11, 2015 Curemark LLC, a ... start of a new Phase III double blind, randomized, ... novel formulation, CM-AT, on all children ages 3-8 with ... FDA Phase III double blinded clinical trial for CM-AT ... levels of the digestive enzyme chymotrypsin. This new trial ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/21/2015)... 21, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... medicine company focused on the development of autologous ... at the International Society for Cellular Therapy (ISCT) ... tendinosis currently in a Phase 1/2 clinical trial.  ... from 5:30 PM to 7:00 PM local ...
(Date:5/21/2015)... Prussia, PA (PRWEB) May 21, 2015 ... O’Neill has joined the firm as senior statistician and ... 30 years of experience in the management and analysis ... biologics, pharmaceutical and chemical industries. , “We’re delighted to ... longstanding capabilities in data analytics,” said Dr. Philippe Cini, ...
(Date:5/20/2015)... and Markets ( http://www.researchandmarkets.com/research/x4b7kw/top_technologies ) has announced ... Insights" report to their offering. Technical ... the Health and Wellness sector and has identified top ... in the year 2015. The research service provides an ... wellness technologies that are anticipated to have the highest ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
Breaking Biology Technology:RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
Cached News: